Physician profile
Robert P Young
NPI 1013910744
$1,276.74
in general payments reported to CMS, 2019-2025
14 companies · $96.34 in 2025
The $96.34 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $46.18 · 2020: $37.94 · 2021: $643 · 2022: $56.67 · 2023: $96.21 · 2024: $301 · 2025: $96.34.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $493.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $493.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $464.06 | 2019-2021 | |
| Abbvie INC. | $239.10 | 2020-2024 | Botox |
| Allergan, INC. | $134.37 | 2019-2022 | |
| Dermavant Sciences, INC. | $87.58 | 2022-2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $83.94 | 2019-2025 | |
| Galderma Laboratories, L.P. | $71.68 | 2024-2025 | |
| Amgen INC. | $46.81 | 2022-2024 | Otezla |
| Regeneron Healthcare Solutions, INC. | $33.48 | 2021-2024 | Dupixent |
| Leo Pharma INC. | $26.57 | 2025 | Adbry |
| Janssen Biotech, INC. | $22.14 | 2024 | Tremfya |
| Arcutis Biotherapeutics, INC. | $19.02 | 2024 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $16.35 | 2024 | Sotyktu |
| Lilly USA, LLC | $16.02 | 2024 | Ebglyss |
| Smith+Nephew, INC. | $15.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.